Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation. by Jevnikar, Zala et al.
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
74
95
 
| 
do
wn
lo
ad
ed
: 
27
.1
.2
02
0Epithelial IL-6 trans-signaling defines a new asthma
phenotype with increased airway inflammationZala Jevnikar, PhD,a J€orgen €Ostling, PhD,a Elisabeth Ax, MSc,a,b Jenny Calven, PhD,a Kristofer Th€orn, PhD,a
Elisabeth Israelsson, PhD,a Lisa €Oberg, MSc,a Akul Singhania, PhD,c Laurie C. K. Lau, PhD,c Susan J. Wilson, PhD,c,d
JonathanA.Ward,BSc,c,dAnoopChauhan,MD,PhD,eAnaR.Sousa,PhD,fBertrandDeMeulder,PhD,gMatthewJ.Loza,PhD,h
Frederic Baribaud, PhD,h Peter J. Sterk, MD, PhD,i Kian Fan Chung, MD, DSc,j Kai Sun, PhD,k Yike Guo, PhD,k
Ian M. Adcock, PhD,j Debbie Payne, BSc,l Barbro Dahlen, MD, PhD,m Pascal Chanez, MD, PhD,n Dominick E. Shaw, MD,o
Norbert Krug,MD,p JensM.Hohlfeld,MD,p,q ThomasSandstr€om,MD, PhD,r RatkoDjukanovic,MD, PhD,s Anna James, PhD,t
Timothy S. C. Hinks, MD, PhD,c,s,u Peter H. Howarth, MD, PhD,c,s Outi Vaarala, MD, PhD,a Marleen van Geest, PhD,a* and
Henric Olsson, PhD,a* the Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes study group
Gothenburg, Stockholm, andUmea, Sweden; Southampton, Portsmouth, Brentford, London,Manchester, Nottingham, andOxford,UnitedKingdom;
Lyon and Marseille, France; Springhouse, Pa; Amsterdam, The Netherlands; and Hannover, Germany
GRAPHICAL ABSTRACTEuropean Union and from the European Federation of Pharmaceutical Industries andFrom athe Department of Bioscience, Respiratory, Inflammation and Autoimmunity,IMED Biotech Unit, AstraZeneca, Gothenburg; bthe Department of Internal Medicine
and Clinical Nutrition, Krefting Research Centre, Institute of Medicine, University of
Gothenburg; cClinical and Experimental Sciences, University of Southampton Faculty
of Medicine, and sthe NIHR Southampton Respiratory Biomedical Research Unit,
Southampton University Hospital; dthe Histochemistry Research Unit, Faculty of
Medicine, University of Southampton; ePortsmouth Hospitals NHS Trust, Portsmouth;
fDiscovery Medicine, GlaxoSmithKline, Brentford; gthe European Institute for Sys-
tems Biology and Medicine, CIRI UMR5308, CNRS-ENS-UCBL-INSERM, Uni-
versite de Lyon; hJanssen R&D, Johnson & Johnson, Springhouse; ithe Department
of Respiratory Medicine, Academic Medical Center, Amsterdam; jthe National Heart
and Lung Institute, Imperial College London, London UK & Royal Brompton
Biomedical Research Unit at Royal Brompton and Harefield NHS Foundation Trust
and Imperial College London; kthe Department of Computing & Data Science Insti-
tute, Imperial College London; lthe Centre for Integrated Genomic Medical Research,
University of Manchester; mKarolinska University Hospital & Centre for Allergy
Research and tExperimental Asthma and Allergy Research, Institute of Environmental
Medicine, Karolinska Institute, Stockholm; nUniversite de la Mediterranee, Marseille;
othe Respiratory Biomedical Research Unit, University of Nottingham; pthe
Fraunhofer Institute of Toxicology and Experimental Medicine, Member of the
German Center for Lung Research, Hannover; qthe Department of Respiratory Medi-
cine, Hannover Medical School; rthe Department of Public Health and Clinical Med-
icine, Medicine, Umea University, Umea; and uthe Respiratory Medicine Unit, NDM
Experimental Medicine, University of OxfordJohn Radcliffe Hospital, Oxford.
*These authors contributed equally to this work as co-senior authors.
A list of the Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes
(U-BIOPRED) Study Group authors can be found in the acknowledgements section.
Supported by the IMED Biotech Unit, AstraZeneca. E.A. was supported by the Swedish
Foundation for Strategic Research (SSF). The Unbiased Biomarkers in Prediction of
Respiratory Disease Outcomes (U-BIOPRED) Consortium receives funding from the
Associations as an IMI JU funded project (no. 115010). The Wessex Severe Asthma
Cohort was funded by the Medical Research Council (G0800649). T.S.C.H. was
supported by Wellcome Trust Clinical Research Fellowship (088365/z/09/z and
104553/z/14/z) and by the Academy of Medical Sciences. Infrastructure support was
funded by the NIHR Southampton Respiratory Biomedical Research Unit. We
acknowledge the support of the National Institute for Health Research through the
Primary Care Research Network and through an Academic Clinical Fellowship (to
T.S.C.H.). A.S. was supported by the Faculty of Medicine, University of Southampton.
I.M.A. and K.F.C. are supported by the NIHRRespiratory Disease Biomedical Research
Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College
London. I.M.A. is also supported by the Wellcome Trust (076472/2/05/Z).
Disclosure of potential conflict of interest: Z. Jevnikar, J. €Ostling, E. Ax, K. Th€orn, E.
Israelsson, L. €Oberg, O. Vaarela, M. van Geest, and H. Olsson are employees of
AstraZeneca, which supported the study. M. J. Loza and F. Barobaud are employees
and shareholders of Janssen R&D. The rest of the authors declare that they have no
relevant conflicts of interest.
Received for publication October 11, 2017; revised April 15, 2018; accepted for publica-
tion May 4, 2018.
Available online June 11, 2018.
Corresponding author: Zala Jevnikar, PhD, Senior Research Scientist, The Department of
Bioscience, Respiratory, Inflammation and Autoimmunity, IMED Biotech Unit, Astra-
Zeneca, Gothenburg, Sweden. E-mail: Zala.Rojnik@astrazeneca.com.
The CrossMark symbol notifies online readers when updates have been made to the
article such as errata or minor corrections
0091-6749
 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jaci.2018.05.026
577
Abbreviations used
ALI: Air-liquid interface
BALF: Bronchoalveolar lavage fluid
HBEC: Human bronchial epithelial cell
IL-6TS: IL-6 trans-signaling
IPA: Ingenuity Pathway Analysis
JAK: Janus kinase
MIP: Macrophage inflammatory protein
MMP: Matrix metalloproteinase
sIL-6R: Soluble IL-6 receptor
STAT: Signal transducer and activator of transcription
T2: Type 2
TLR: Toll-like receptor
U-BIOPRED: Unbiased Biomarkers in Prediction of Respiratory
Disease Outcomes
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578 JEVNIKAR ET ALBackground: Although several studies link high levels of IL-6
and soluble IL-6 receptor (sIL-6R) to asthma severity and
decreased lung function, the role of IL-6 trans-signaling (IL-
6TS) in asthmatic patients is unclear.
Objective: We sought to explore the association between
epithelial IL-6TS pathway activation and molecular and clinical
phenotypes in asthmatic patients.
Methods: An IL-6TS gene signature obtained from air-liquid
interface cultures of human bronchial epithelial cells stimulated
with IL-6 and sIL-6R was used to stratify lung epithelial
transcriptomic data (Unbiased Biomarkers in Prediction of
Respiratory Disease Outcomes [U-BIOPRED] cohorts) by
means of hierarchical clustering. IL-6TS–specific protein
markers were used to stratify sputum biomarker data (Wessex
cohort). Molecular phenotyping was based on transcriptional
profiling of epithelial brushings, pathway analysis, and
immunohistochemical analysis of bronchial biopsy specimens.
Results: Activation of IL-6TS in air-liquid interface cultures
reduced epithelial integrity and induced a specific gene
signature enriched in genes associated with airway remodeling.
The IL-6TS signature identified a subset of patients with IL-
6TS–high asthma with increased epithelial expression of IL-
6TS–inducible genes in the absence of systemic inflammation.
The IL-6TS–high subset had an overrepresentation of frequent
exacerbators, blood eosinophilia, and submucosal infiltration of
T cells and macrophages. In bronchial brushings Toll-like
receptor pathway genes were upregulated, whereas expression
of cell junction genes was reduced. Sputum sIL-6R and IL-6
levels correlated with sputum markers of remodeling and innate
immune activation, in particular YKL-40, matrix
metalloproteinase 3, macrophage inflammatory protein 1b, IL-
8, and IL-1b.
Conclusions: Local lung epithelial IL-6TS activation in the
absence of type 2 airway inflammation defines a novel subset of
asthmatic patients and might drive airway inflammation and
epithelial dysfunction in these patients. (J Allergy Clin Immunol
2019;143:577-90.)
Key words: Asthma, lung epithelium, transcriptomics, hierarchical
clustering, IL-6 signaling, exacerbation frequency, eosinophils,
airway inflammation, remodeling, epithelial integrity
Type 2 (T2) inflammation defines one major asthma endotype,
but a significant proportion of asthmatic patients do not express
airway T2 inflammationmarkers and do not respond to treatments
targeting this pathway.1 Thus identification of the cellular and
molecular disease drivers beyond T2 asthma is required to
achieve disease control in these patients.
IL-6 is a pleiotropic cytokine that can be produced bymany cell
types in response to a wide array of inflammatory stimuli and
cytokines.2 In the classical pathway binding of IL-6 to its
membrane-bound receptor (IL-6R) induces recruitment and ho-
modimerization of the signal-transducing receptor glycoprotein
130, which leads to phosphorylation of signal transducer and acti-
vator of transcription (STAT) family transcription factors
(STAT3, STAT1, or both) by the Janus tyrosine kinase family (Ja-
nus kinase [JAK] 1, JAK2, and tyrosine kinase 2). In addition, it
causes activation of the mitogen-activated protein kinase and
phosphoinositide 3-kinase cascades.3,4 Classical signaling isprominent in cells expressing high levels of IL-6R on their sur-
faces, such as neutrophils, macrophages, and some types of T
cells.5 In contrast, cell types with no or low expression of mem-
brane IL-6R depend on IL-6 trans-signaling (IL-6TS) mediated
by the soluble IL-6 receptor (sIL-6R), which associates with
glycoprotein 130 after forming a complex with IL-6.6 sIL-6R is
produced as a result of alternative mRNA splicing7 or through
shedding of IL-6R from the cell surface by a disintegrin and met-
alloprotease and meprin proteases8,9 in response to various in-
flammatory signals, such as C-reactive protein, IL-8, CXCL1,
bacterial pore-forming toxins, and LPS.10-13 Neutrophils have
been proposed as the main source of sIL-6R generated at sites
of inflammation,11 and a recent study showed that neutrophils
might be an important source of sIL-6R in the lungs of asthmatic
patients.14
Increased levels of IL-6 have been found in serum, sputum, and
bronchoalveolar lavage fluid (BALF) of asthmatic patients15-17
and also in BALF from patients with nonallergic asthma
compared with that from patients with allergic asthma, suggesting
a role for IL-6 in non-T2 asthma.18 Supporting this, a recent study
conducted in the University of California, San Francisco and Se-
vere AsthmaResearch Program asthma cohorts identified a strong
association between high systemic IL-6 levels and asthma
severity, whereas no correlation was found between IL-6 and
T2 inflammation biomarkers, including blood and sputum eosin-
ophil counts, blood IgE levels, and fraction of exhaled nitric oxide
values.19 As for IL-6, sIL-6R levels have been found to be signif-
icantly increased in serum,20 BALF,21 and sputum22 from asth-
matic patients compared with those from control subjects.
A role for IL-6 as an asthma disease driver is also emerging
from genetic evidence, and a genome-wide association study re-
vealed an association between the single nucleotide polymor-
phism rs4129267 in intron 8 of the IL6R gene and an increased
asthma risk.23
In this study we identified an IL-6TS–driven patient subset in
the Unbiased Biomarkers in Prediction of Respiratory Disease
Outcomes (U-BIOPRED) cohorts24 based on an epithelial IL-
6TS–specific gene signature. These patients were characterized
by their unique clinical and histopathologic features, including
a history of frequent exacerbations and a remarkable increase in
submucosal T-cell and macrophage infiltration, and they also
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airway remodeling.METHODS
Primary cell culture and activation
Primary human bronchial epithelial cells (HBECs; Lonza, Basel,
Switzerland) were expanded to passage 2 in BEGM Bronchial Epithelial
Cell Growth Medium (Lonza). These cells were then seeded on 0.4-mm
Corning HTS Transwell 24-well permeable supports (Sigma-Aldrich, St
Louis, Mo) coated with PureCol (Advanced BioMatrix, Carlsbad, Calif) and
differentiated at the air-liquid interface (ALI) using PneumaCult-Ex and ALI
Media (STEMCELL Technologies, Vancouver, British Columbia, Canada),
according to the manufacturer’s protocol. Once fully differentiated, cells were
stimulated for 3 to 48 hours by means of basolateral addition of the human
recombinant proteins IL-4 and IL-13 (30 ng/mL; R&D Systems, Minneapolis,
Minn) or IL-6 and sIL-6R (10-150 ng/ml; PeproTech, Rocky Hill, NJ) diluted
in PneumaCult-ALI medium. JAK1 inhibitor (1 mmol/L)25 or dimethyl sulf-
oxide were added apically for 30 minutes in 200 mL of medium that was
removed before stimulation. Phosphorylation of STAT3 on tyrosine 705 was
quantified with a pSTAT3 detection kit (Meso Scale Discovery, Rockville,
Md), according to the manufacturer’s instructions.Patient cohorts, transcriptomics, and proteomics
The U-BIOPRED study was a cross-sectional observational study using
baseline visits of the U-BIOPRED cohorts from 16 clinical centers in 11
countries across Europe. It included steroid-treated adults with asthma
classified and treated according to the Global Initiative for Asthma guidelines,
as well as healthy control subjects. Definitions for each group of subjects and
collection of clinical variables have been published previously by Shaw et al.24
The current study usd data from 147 subjects from the U-BIOPRED asthma
cohorts, including patients with mild-to-moderate asthma (n 5 36), patients
with severe asthma (n 5 49), smokers with severe asthma (n 5 18), and
healthy nonsmoking control subjects (n 5 44) who underwent fiberoptic
bronchoscopy for central airway epithelial cell brushings.26 Transcriptomic
data from brushings were obtained by using a HT HG-U1331 PMmicroarray
platform (Affymetrix Plus 2.0; Affymetrix, Santa Clara, Calif), as previously
described.27 Affymetrix Plus 2.0 microarray data were downloaded from the
U-BIOPRED/tranSMART database (August 2016 version). Blood samples
were collected,24 and biomarkers (IL-6 and sIL-6R) were analyzed by using
the SomaScan v3 platform (SomaLogic, Boulder, Colo), as previously
described.28Unsupervised hierarchical clustering
Hierarchical clustering of U-BIOPRED gene expression data was
performed by using the average linkage and Euclidean metric methods, with
each variable normalized to a mean of 0 and variance of 1 by using Qlucore
Omics Explorer 3 (Qlucore, Lund, Sweden). Results were visualized as
dendrogram heat maps in which the color scale is given as the log2 fold change
with a range from 22.0 (blue) through 0.0 (grey) to 12.0 (red). Data from
multiple probes were collapsed to single genes by using the highest value.Statistical analysis
Gene expression data were log2 transformed and analyzed by using general
linear model–based statistical tests adjusting for age, sex, and site code with
Qlucore Omics Explorer 3.3 (Qlucore). Benjamini-Hochberg multiple correc-
tion was used to control for the rate of false-positive results (referred to as q
value). Statistical analysis of clinical variables and biomarker data was per-
formed with Kruskal-Wallis tests in Spotfire 7.0.2 (TIBCO Spotfire). The P
value for MetaCore (MetaCore; Thomson Reuters, Toronto, Ontario, Canada)
pathway analysis and Ingenuity Pathway Analysis (IPA; Qiagen, Hilden, Ger-
many) was calculated by using the right-tailed Fisher exact test. All statistical
analyses of in vitro data were performed with the 2-tailed unpaired t test. Alldata analyses, except analysis of gene expression data, were considered hy-
pothesis based, and significance was reached at a P value of .05 or less. Cor-
relations were tested with Spearman r statistics. Prism 6.0 software (GraphPad
Software, La Jolla, Calif) was used for data analysis and graphic
representation.RESULTS
IL-6TS induces a specific gene expression profile
distinct from the T2 inflammation gene signature in
primary bronchial epithelial cells
Stimulation of primary HBECs grown as ALI cultures with
either recombinant IL-6 alone (classical IL-6 signaling) or in
combination with sIL-6R (IL-6TS) induced robust STAT3
phosphorylation within 30 minutes. The increase in STAT3
phosphorylation was considerably stronger in the presence of
sIL-6R, which was added at a concentration (150 ng/mL)
comparable with the levels found in sera of asthmatic patients.20
Moreover, only IL-6TS led to persistent STAT3 phosphorylation
after prolonged exposure with daily applications of IL-6 or IL-6/
sIL-6R (Fig 1, A). Pretreating cells with a JAK1-selective inhibi-
tor25 abrogated STAT3 phosphorylation induced by IL-6TS
(Fig 1, B and C).
To identify genes regulated by IL-6TS, we stimulated HBEC
ALI cultures for 24 hours with IL-6/sIL-6R, followed by global
gene expression analysis using RNA sequencing. In total, 8781
protein-coding genes (q < 0.05) were expressed differentially be-
tween IL-6/sIL-6R (IL-6TS)–stimulated and unstimulated con-
trol cells, whereas 6514 genes were affected by IL-6 alone. All
genes regulated by both IL-6 and IL-6/sIL-6R (6041 overlapping
genes) had a consistent direction of change, and IL-6/sIL-6R
consistently produced a stronger expression of the majority of
these genes than IL-6 on its own (Fig 1, D, and see Tables E1
and E2 in this article’s Online Repository at www.jacionline.
org). Expression of selected IL-6TS–inducible genes was vali-
dated by using quantitative PCR in 3 additional donors (see Fig
E1 in this article’s Online Repository at www.jacionline.org).
Several of the genes that were strongly induced by IL-6TS have
been associated with airway remodeling in patients with respira-
tory diseases and include genes for matrix metalloproteinases
([MMPs];MMP1,MMP3, andMMP12),29 chitinase-like proteins
(CHI3L1/YKL-40 and CHI3L2/YKL-39),30 osteopontin
(SPP1),31 and IL-33.32 The exact biological role of YKL-40 in
asthmatic patients remains unclear, but it correlates consistently
with airway obstruction and measures of airway remodeling,
such as thickness of the bronchial wall.30,33 MMP3 expression
has been found to be increased in BALF of patients with severe
asthma,34 and it has been implicated in emphysematous airway
remodeling in patients with chronic obstructive pulmonary
disease.35 Specific induction of YKL-40 and MMP3 by
IL-6/sIL-6R was confirmed also on protein levels in 6 different
HBEC donors (Fig 1, G).
As controls, we stimulated the HBEC ALI cultures with a
combination of IL-4 and IL-13 to induce a typical T2 inflamma-
tory gene profile, as confirmed by increased expression of T2
signature genes, including CCL26 and NOS2, which was previ-
ously reported by Choy et al.36 The IL-4/IL-13–induced gene
signature was distinct from the IL-6TS gene signature, and T2
stimulation of HBEC ALI cultures had no effect or only a weak
effect on the majority of IL-6TS–specific genes (Fig 1, D-F; see
Fig E2, A, and Table E3 in this article’s Online Repository at
FIG 1. IL-6TS induces a specific JAK1-dependent gene expression pattern that is distinct from the T2
inflammation signature in ALI cultures. Primary HBEC ALI cultures were stimulated with IL-6, IL-6/sIL-6R, or
IL-4/IL-13. Cells were pretreated (30 minutes) with a JAK1 inhibitor (JAK1i) or dimethyl sulfoxide (DMSO)
control, where indicated. A-C, STAT3 phosphorylation. Fig 1, A and B, Data are representative of 2 indepen-
dent experiments. Fig 1, C, Three different HBEC donors (means and SDs).D and E, Cells were stimulated for
24 hours, and gene expression was assessed by using RNA sequencing, normalized, and compared with
nonstimulated control. The most upregulated genes are shown as heat maps of log2 fold change. F, Expres-
sion of indicated genes was analyzed by using quantitative PCR. Mean log2 fold change values from 3 HBEC
donors are shown.G, Secreted levels of YKL-40 andMMP3 after 24 hours of stimulation with IL-6 and sIL-6R
from 6 HBEC donors. H, Cells were stimulated for 24 hours with IL-6/sIL-6R. The effect of IL-6/sIL-6R (vs
DMSO, first column) and the effect of JAK1i on IL-6/sIL-6R stimulation (IL-6/sIL-6R/JAK1i vs IL-6/sIL-6R/
DMSO, second column) for the top-induced genes in Fig 1, D, is shown as a heat map of log2 fold change.
*P < .05, **P <_ .01, ***P <_ .001, and ****P <_ .0001, unpaired t test. NS, Nonstimulated control.
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FIG 2. The IL-6TS–specific gene signature in bronchial epithelium defines a new IL-6TS–high patient subset
within the U-BIOPRED asthma cohorts. A, Hierarchical clustering of patients with transcriptomic data
derived from bronchial brushings (n 5 103) using the IL-6TS–specific gene signature (TNFAIP6, PDE4B,
IL1R2, S100A9, S100A8, S100A12, CHI3L1, and SPP1). High gene expression is denoted in red, and low
expression is denoted in blue. The subset of patients with increased IL-6TS gene signature (IL-6TS high)
is highlighted (red box).B, Serum levels of IL-6 and sIL-6R presented as change in relative fluorescence units
(RFU). C,Gene expression scores for the main IL-6/JAK/STAT3 pathway genes in bronchial brushings calcu-
lated from normalized and zero-centered gene expression values. Protein (Fig 2, B) and mRNA (Fig 2, C)
levels from the IL-6TS–high group (n 5 17) were compared with those in the rest of the asthmatic patients
(IL-6TS–low group, n5 86) and healthy control subjects (n5 44). Statistically significant differences are indi-
cated (Kruskal-Wallis test for protein levels: P <_ .05; Benjamini-Hochberg test for gene expression: q <_ 0.05).
D, Percentage of subjects with high expression of epithelial T2 inflammation–specific gene signature. The
distribution of patients with T2 asthmawas not significantly different (P5 .70, x2 test) between the 2 groups.
ns, Not significant.
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sion was strongly reduced in the presence of the JAK1 inhibitor,
confirming the essential role of the JAK/STAT pathway for down-
stream IL-6 signaling in lung epithelium (Fig 1,H, and see Fig E2,
B, and Table E4 in this article’s Online Repository at www.
jacionline.org). Raw and processed data of all RNA sequencing
experiments are deposited in the National Center for Biotech-
nology Information GEO database (accession no. GSE113185).IL-6TS–specific gene signature in lung epithelium
defines a novel subset of asthmatic patients
To investigate whether the IL-6TS pathway is activated in
airway epithelium of patients with asthma, we analyzed the
transcriptomic data derived from 103 central airways epithelial
brushings from the U-BIOPRED asthma cohorts, including
patients with mild-to-moderate (n 5 36) and severe (n 5 49)
asthma and smokers with severe asthma (n 5 18). Hierarchical
clustering analysis based on the genes most strongly induced by
IL-6TS in HBEC ALI cultures identified a set of 8 coclustered
genes (TNFAIP6, PDE4B, IL1R2, S100A9, S100A8, S100A12,CHI3L1, and SPP1) that defined a clear subset of patients
(n 5 17) with increased expression of these IL-6TS–inducible
genes (referred to here as the IL-6TS–high subset; Fig 2, A). Un-
expectedly, this IL-6TS–high subset did not show increased
levels of systemic IL-6 and sIL-6R compared with the remaining
asthmatic patients (n 5 86; referred to here as the IL-6TS–low
subset) or healthy control subjects (n 5 95; Fig 2, B). The IL-
6TS–high subset showed a robust increase in expression of the
main IL-6/JAK/STAT3 pathway genes, such as MCL1, SOCS3,
and MAPKAPK2,37 compared with the IL-6TS–low subset and
healthy control subjects (Fig 2, C), confirming the connection
between the IL-6TS–high subset and IL-6 signaling. Taken
together, these results suggest that the identified IL-6TS–high
subset is driven by local rather than systemic IL-6 pathway
activation.
The same group of patients (apart from smokers) was clustered
based on expression of the T2 gene signature (POSTN, CLCA1,
and SERPINB2), which was previously shown to be a hallmark
of T2 inflammation,38 to examine the IL-6TS–high subset in rela-
tion to T2 inflammation. Therewas no enrichment of patients with
the epithelial T2 signature in the IL-6TS–high subset (Fig 2, D).
TABLE I. Clinical characteristics of the IL-6TS–high versus IL-6TS–low subsets from the U-BIOPRED asthma cohorts
Parameter IL-6TS-high IL-6TS-low P value
Group size 17 86
Female sex (%) 41.2 53.5 .35
Body mass index (kg/m2) 28.3 6 1.6 29.1 6 0.6 .70
Age (y) 43.9 6 3.9 46.2 6 1.5 .59
Patients with severe asthma (%) 70.0 64.0 .6
Smokers with severe asthma (%) 11.8 18.6 .5
Never smokers (%) 70.6 68.6 .87
Pack years 17.8 6 12.1 16.0 6 3.5 .78
ICS, high dose (%) 70.6 63.9 .60
Maintenance OCS (%) 37.5 (n 5 16) 26.8 (n 5 82) .39
FEV1 (% predicted) 77.8 6 5.8 80.7 6 2.3 .56
Exacerbations (no./previous year) 3.0 (2.3-4.0 [n 5 10]) 2.0 (1.0-3.0 [n 5 52]) .096
Exacerbations, >_3/previous year (%) 70.0 (n 5 10) 36.5 (n 5 52) .049*
History of exacerbations (no./year) 2.5 (0.0-4.0 [n 5 16]) 1 (0.0-2.0) .13
History of exacerbations, >_3/y (%) 50.0 (n 5 16) 23.3 .028*
Positive atopic status (%) 87.5 (n 5 16) 79.0 (n 5 76) .43
Total IgE (IU/mL) 131 (43-566) 105 (40-290) .48
Serum CRP (mg/mL) 2 (0.6-5.0) 1.4 (0.6-3.2) .64
FENO (ppb) 22.7 (19.0-48.8 [n 5 16]) 23.8 (16.0-54.5 [n 5 82]) .98
Blood eosinophils (3 1000/mL) 0.3 (0.14-0.5) 0.2 (0.1-0.3) .050*
Blood eosinophils, >300/mL (%) 47.0 15.1 .0028*
Sputum eosinophils (%) 1.7 (0.8-26.2 [n 5 10]) 0.7 (0-4.6 [n 5 33]) .14
Sputum eosinophils, >3% (%) 40.0 (n 5 10) 33.3 (n 5 33) .70
Sputum eosinophils, >20% (%) 40.0 (n 5 10) 6.1 (n 5 33) .007*
Blood neutrophils (3 1000/mL) 4.4 (3.4-7.3) 4.1 (3.0-5.9) .46
Sputum neutrophils (%) 61.9 (47.7-76.5 [n 5 10]) 45.3 (31.9-63.4 [n 5 33]) .13
Sputum neutrophils, >60% (%) 50.0 (n 5 10) 30.3 (n 5 33) .25
Sputum macrophages (%) 16.7 (7.2-28.4 [n 5 10]) 44.0 (27.6-63.7 [n 5 33]) .0089*
Sputum macrophages (no.) 125.0 6 36.9 (n 5 10) 235.3 6 20.7 (n 5 33) .011*
Submucosal CD31 T cells (cells/mm2) 70.8 6 15.0 (n 5 17) 35.7 6 3.6 (n 5 70) .0008*
Submucosal CD41 T cells (cells/mm2) 29.3 6 6.3 (n 5 17) 10.9 6 1.3 (n 5 70) .00007*
Submucosal CD81 T cells (cells/mm2) 38.2 6 6.9 (n 5 17) 17.2 6 1.9 (n 5 70) .0003*
Submucosal CD681 macrophages (cells/mm2) 7.0 6 1.3 (n 5 17) 3.1 6 0.4 (n 5 70) .0011*
Data are presented as percentages, means 6 SEs, or medians (interquartile ranges [Q1-Q3]). Number of subjects is 17 in the IL-6TS–high subset and 86 in the IL-6TS–low subset,
unless stated otherwise. For P values, the Kruskal-Wallis test was used for continuous data, and the x2 test was used for categorized data.
CRP, C-reactive protein; FENO, fraction of exhaled nitric oxide; ICS, inhaled corticosteroids; ICS, high dose, 1000 mg or more fluticasone or equivalent; OCS, oral corticosteroids.
*Statistically significant (P <_ .05).
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frequent exacerbations, eosinophilic airway
inflammation, and increased numbers of T cells and
macrophages infiltrating the airway submucosa
The IL-6TS–high and IL-6TS–low subsets did not differ in
respect to sex, steroid treatment, atopic status, or smoking history.
The proportion of patients with 3 or more exacerbations per year
was significantly greater in the IL-6TS–high subset compared
with the IL-6TS–low subset (Table I and see Fig E3 in this arti-
cle’s Online Repository at www.jacionline.org). Furthermore,
the number of patients with blood (>300 cells/mL) and sputum
(>20%) eosinophilia was significantly increased in the IL-6TS–
high subset, whereas the absolute numbers and proportions of
sputum macrophages were decreased compared with those in
the IL-6TS–low subset. Previous studies have shown IL-6 to be
associated with neutrophilic inflammation,19,39 but even though
we observed a trend toward increased sputum neutrophil numbers
in the IL-6TS–high subset compared with the IL-6TS–low subset,
the difference did not reach statistical significance.
Immunohistochemical analysis of bronchial biopsy specimens
showed significantly greater numbers of total immune cells,including mast cells, neutrophils, eosinophils, T cells, and
macrophages, in the submucosa of patients with IL-6TS–high
versus IL-6TS–low asthma (Fig 3, A). This difference was driven
mainly by a striking increase in infiltration of CD31, CD41, and
CD81 T cells and CD681 macrophages (P5 .0008, P5 .00007,
P 5 .0003, and P 5 .001, respectively) but not by granulocytes
(Fig 3, B and C, and Table I).Reduced expression of genes related to lung
epithelial barrier function in the IL-6TS–high patient
subset
We found reduced expression of several genes involved in
barrier function in epithelial brushings from the IL-6TS–high
subset, with major differences observed for expression of the
epithelial cell junction components b-catenin (CTNNB1); clau-
dins 1, 8, and 18 (CLDN1/CLDN8/CLDN18); and the gene en-
coding zonula occludens-1 (all q < 0.05), whereas there was
no difference in expression of occludin (OCLN; Fig 4, A).
To evaluate the functional effect of IL-6TS on epithelial barrier
integrity in vitro, we performed prolonged stimulation of HBEC
FIG 3. The U-BIOPRED IL-6TS–high subset is characterized by significantly higher numbers of T-cell and
macrophage infiltration in the submucosa. Immunohistochemical analysis of immune cells in glycol
methacrylate resin–embedded biopsy specimens from patients with IL-6TS–high (n 5 17) and IL-6TS–low
(n 5 70) asthma from the U-BIOPRED asthma cohorts. A, Total immune cells. B, AA11mast cells, elastase-
positive neutrophils, and EG21 eosinophils. C, CD31, CD41 and CD81 T cells and CD681macrophages. Sta-
tistically significant differences (P <_ .05, Kruskal-Wallis test) are indicated. ns, Not significant.
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not IL-6 or sIL-6R on their own, resulted in extensive loss of
epithelial integrity, asmeasured based on transepithelial electrical
resistance (Fig 4,B andC). These results suggest that IL-6TS con-
tributes specifically to compromised epithelial integrity as a
feature of asthma involving local activation of the IL-6TS
pathway.Transcriptional profiling links the IL-6TS–high
subset with immune cell migration and Toll-like
receptor signaling
Separation of the identified IL-6TS–high subset from the rest of
the patients was evident alsowhen comparing global transcription
profiles (20,233 available mRNAs) in lung epithelial brushings.
Remarkably, a total of 4417 transcripts were expressed differen-
tially (q < 0.05) in the IL-6TS–high subset compared with the
IL-6TS–low subset, and 6491 transcripts were expressed differen-
tially compared with healthy subjects.
Involvement of the differentially expressed transcripts in the
IL-6TS–high subset in specific pathophysiologic processes was
investigated by using IPA disease function analysis. This showed
a striking enrichment of genes involved in activation of cell
movement, especially migration and chemotaxis of leukocytes
(see Table E5 in this article’s Online Repository at www.
jacionline.org), an observation well-aligned with the increased
submucosal infiltration of immune cells detected in the IL-6TS–
high subset (Fig 3). Activation of the same cell migration func-
tions emerged after analysis of the transcripts induced by IL-6/
sIL-6R stimulation of ALI cultures, providing a furtherconnection between IL-6TS signaling and immune cell infiltra-
tion, as observed in the IL-6TS–high subset (see Table E5).
MetaCore pathway analysis identified Toll-like receptor (TLR)
signaling as the most strongly activated pathway in the IL-6TS–
high subset (see Table E6 in this article’s Online Repository at
www.jacionline.org), which is in agreement with identification
of TLR2, TLR4,MYD88, and CD14 as upregulated genes in these
subjects (Fig 5, A). In addition, there was increased expression of
TREM1, which is known to cooperate with TLR signaling,40 and
several proinflammatory mediators directly induced by TLR2 and
TLR4, such as IL8, CCL4 (macrophage inflammatory protein
[MIP] 1b), IL-1b, IL6, and TNF-a (Fig 5).Confirmation of the IL-6TS–high asthma subset in
independent replication cohorts
Next, we sought to confirm the existence of an IL-6TS–high
subset in 2 independent replication cohorts of asthmatic patients.
Hierarchical clustering of transcriptomic data based on the IL-
6TS–specific 8-gene signature was done in a cohort including 38
patients with mild-to-moderate or severe asthma (replication
cohort 1)41,42 and in a cohort including 17 patients with severe
asthma (replication cohort 2) with epithelial brushing samples
from central and/or peripheral airways.43 This analysis clearly
clustered patients from both cohorts into an IL-6TS–high and
an IL-6TS–low subsets (see Fig E4, A and B, in this article’s On-
line Repository at www.jacionline.org). Importantly, the IL-6TS–
high subset was again associated with gene upregulation related
to TLR signaling, including TLR2, MYD88, TREM1, and CCL4
(see Fig E4, C).
FIG 4. Decreased expression of epithelial junction proteins in patients with IL-6TS–high asthma from the U-
BIOPRED cohorts. A,mRNA levels of epithelial junction components in bronchial brushings from the U-BIO-
PRED asthma cohorts. Gene expression from the IL-6TS–high group (n5 17) was compared with that in the
rest of the asthmatic patients (IL-6TS–low group, n5 86) and healthy control subjects (n5 44). Gene expres-
sion scores, calculated from normalized and zero-centered gene expression values, are shown. Statistically
significant differences are indicated. q <_ 0.05, Benjamini-Hochberg test. ns, Not significant. B, Transepithe-
lial electrical resistance (TEER) was measured in HBEC ALI cultures after stimulation with sIL-6R (150 ng/
mL), IL-6 (150 ng/mL), and IL-6/sIL-6R (both 150 ng/mL). Data are representative of 2 independent experi-
ments. **P <_ .01 and ***P <_ .001, unpaired t test. C, Effect of IL-6TS on reduction of epithelial integrity after
48 hours of stimulation with 20 ng/mL IL-6 and 50 ng/mL sIL-6R was confirmed in 6 different HBEC donors.
***P <_ .001, unpaired t test. NS, Nonstimulated control.
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MMP3, IL-8, MIP-1b, and IL-1b define an IL-6TS–
high subset in the Wessex Severe Asthma Cohort
A putative IL-6TS–high patient subset was identified by means
of hierarchical clustering of asthmatic patients (n 5 146; British
Thoracic Society [BTS] groups 4 and 5) from the Wessex Severe
Asthma Cohort22 based on levels of 5 sputum biomarkers associ-
ated strongly with IL-6TS, namely YKL-40 andMMP3 surrogate
biomarkers induced by IL-6TS stimulation of ALI cultures
in vitro (Fig 1, F and G) and IL-8, MIP-1b, and IL-1b, which
were found to be significantly overexpressed in epithelial brush-
ings of IL-6TS–high patients from the U-BIOPRED cohort (Fig
5, B).
TheWessex IL-6TS–high subset (n5 24) was comparablewith
the U-BIOPRED IL-6TS–high subset in size (around 16% of the
asthmatic patients in both cohorts), as well as in clinical
characteristics (Fig 6, A, and Table II), including significantly
increased blood eosinophil numbers (P5 .0008), higher percent-
ages of patients with blood eosinophilia (>300 cells/mL;
P 5 .0004), and a reduced proportion of sputum macrophages(P5 .009). In addition, sputum neutrophil counts were increased
in the Wessex IL-6TS–high patient subset (P 5 .01).
Importantly, the Wessex IL-6TS–high subset was associated
with significantly increased levels of sputum sIL-6R (P < .0001)
and IL-6 (P < .0001), whereas there was no difference in serum
C-reactive protein levels (Fig 6, B-D), providing evidence for a
local IL-6TS–driven inflammation. Also, there was no difference
in levels of classical T2 biomarkers, including serum periostin
(Fig 6, E) or sputum IL-5 and eotaxin (see Fig E5, E and F, in
this article’s Online Repository at www.jacionline.org).DISCUSSION
Although increased levels of IL-6 and sIL-6R in asthmatic
patients have been observed by others,22,23,44 the molecular un-
derstanding of the role of IL-6 signaling in asthmatic airways is
limited. Herewe generated a gene signature induced by activation
of IL-6TS in HBEC ALI cultures and used this signature to iden-
tify an asthmatic patient subset in the U-BIOPRED cohorts with
signs of lung epithelial IL-6TS pathway activation. We revealed
FIG 5. TLR pathway genes are upregulated in bronchial brushings from U-BIOPRED patients with IL-6TS–
high asthma. mRNA levels of TLR signaling and costimulatory molecules (A) and TLR signaling–inducible
proinflammatory mediators (B) in bronchial brushings from the U-BIOPRED asthma cohorts. Gene expres-
sion from the IL-6TS–high group (n 5 17) were compared with that of the rest of the asthmatic patients (IL-
6TS–low group, n 5 86) and healthy control subjects (n 5 44). Gene expression scores are calculated from
normalized and zero-centered gene expression values. Statistically significant differences are indicated.
q <_ .05, Benjamini-Hochberg test.
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history of frequent exacerbations and significantly increased sub-
mucosal infiltration of T cells and macrophages. Furthermore,
they showed reduced expression of genes regulating epithelial
barrier function and an increased expression of TLR pathway
activation and remodeling genes in their epithelial brushings.
Interestingly, the IL-6TS–high asthma subset had increased blood
eosinophil counts despite not being enriched with patients with
T2 inflammation in the lung epithelium. This suggests that the
eosinophilia observed in the IL-6TS–high subset is disconnected
from T2 inflammation and results in a direct or indirect conse-
quence of IL-6 signaling in the airways. Our results emphasize
that asthmatic patients with eosinophilia need to be further strat-
ified with respect to the biological driver of the eosinophilic lung
infiltration, which might not necessarily be T2 inflammation.38
Although the understanding of the mechanism leading to sys-
temic eosinophilia in the IL-6TS–high subset requires further
study, it is tempting to speculate that IL-6TS promotes the
observed phenotype by inducing IL-33 expression, which is a
potent activator of mature eosinophils,45 and it can also regulate
eosinophil development within the bone marrow46 and tissue.47
In support of this hypothesis, IL33 was one of the genes most
strongly induced on stimulation of primary bronchial epithelial
cells with IL-6/sIL-6R but not with IL-4/IL-13 (Fig 1, D and F,
and see Fig E1, B).
Importantly, despite upregulation of IL-6/JAK/STAT3 pathway
genes in epithelial brushings from the IL-6TS–high subset, thesepatients did not show increased serum IL-6 and sIL-6R levels.
This suggests that the IL-6TS–high subset described in this study
is distinct from the recently described IL-6–high asthma subset
characterized by systemic IL-6 inflammation, metabolic dysfunc-
tion, and obesity19 and instead represents a separate entity with
local IL-6TS–driven airway inflammation.
Activation of the IL-6 pathway has been associated previously
with neutrophilic and mixed granulocytic airway inflammation in
asthmatic patients.48,49 A connection between IL-6–dependent
inflammation and a mixed granulocytic phenotype was observed
also in a mouse cockroach-induced asthma model, where specific
blocking of IL-6TS reduced accumulation of both eosinophils and
neutrophils in BALF.48 However, although the IL-6TS–high sub-
set described in this study was significantly enriched with highly
eosinophilic patients, there were no significant differences in
blood or sputum neutrophil counts between the IL-6TS–high
and IL-6TS–low subsets. Instead, we observed a striking increase
of airway submucosal T-cell populations and macrophages in the
IL-6TS–high subset, indicating increased airway inflammation in
these patients. In line with this observation, a link between the IL-
6TS–high subset and activation of immune cell migration was
shown by using IPA of differentially expressed transcripts be-
tween the IL-6TS–high and IL-6TS–low subsets. The correlation
between IL-6TS and immune cell infiltration is also consistent
with previous studies showing that IL-6TS is essential for macro-
phage and T-cell recruitment to the site of acute inflammation in
mice.11,50 IL-6TS has been proposed to coordinate a temporal
FIG 6. Identifying and characterizing the IL-6TS–high subset in the Wessex Asthma Cohort based on IL-6TS
surrogate biomarkers in sputum. A, Identification of the IL-6TS–high subset in the Wessex Asthma Cohort
by hierarchical clustering of patients (BTS groups 4 and 5, n 5 146) based on high (red) versus low (blue)
expression of the IL-6TS–high surrogate biomarkers YKL-40, IL-8, MIP-1b, IL-1b, and MMP3 in sputum. Sub-
set of patients with increased IL-6TS gene signature (IL-6TS–high group) is highlighted (red box). B and C,
Sputum sIL-6R and IL-6 levels in the Wessex IL-6TS–high subset compared with the IL-6TS–low subset and
healthy control subjects. D and E, Serum C-reactive protein (CRP) and periostin levels in theWessex IL-6TS–
high subset compared with the IL-6TS–low subset and healthy control subjects. Log10 transformed data are
shown. Values of less than the detection range are marked by squares. Median values and statistically sig-
nificant differences are indicated. P <_ .05, Kruskal-Wallis test. ns, Not significant.
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population of mononuclear leukocytes by regulating the expres-
sion of CXC and CC chemokines,11 which could potentially
explain the absence of a strong neutrophilic inflammation compo-
nent in the airways of patients in the U-BIOPRED IL-6TS–high
subset.
Another key feature of the patients with IL-6TS–high asthma
was decreased levels of several cell junction transcripts, with
particularly low levels of claudins (1, 8, and 18) and b-catenin.
Furthermore, we demonstrated that IL-6TS impairs epithelial
integrity in vitro in HBECALI cultures, providing a direct link be-
tween IL-6TS and epithelial dysfunction. Previous reports have
shown that dysfunctional cell junctions are closely connected to
the severity and progression of asthma and that decreased expres-
sion of cell junction proteins, such as zonula occludens-1, clau-
dins, and b-catenin, in asthmatic patients might result in cell
junction disruption and decreasing epithelial barrier function.51-54
Epithelial barrier defects and reduced cell junction integrity in
the intestines are linked to microbial dissemination and inflam-
mation through TLR signaling, and it has been shown that Hae-
mophilus influenzae and Streptococcus pneumoniae exploit
TLR2- and TLR4-mediated downregulation of cell junction com-
ponents to facilitate translocation across the lung epithelium.55-57
Notably, TLR signaling was the most significantly activated
pathway in the IL-6TS–high subset, as shown by using MetaCorepathway analysis of differentially expressed transcripts. In addi-
tion to the significant upregulation of essential TLR pathwaymol-
ecules, patients in the IL-6TS–high subset also exhibited
significantly increased expression of proinflammatory mediators
(IL-8, CCL-4 [MIP-1b], IL-1b, IL-6, and TNF-a) known to be
induced in response to TLR2 and TLR4 triggering.58,59 These re-
sults point to hyperactivation of TLR pathways in response to bac-
terial colonization as one possible cause of the reduced expression
of cell junction proteins and the promotion of submucosal inflam-
mation. An important clinical phenotype of the IL-6TS–high sub-
set was the history of frequent exacerbations, which could be
related to colonization of the airways, with pathogens such as H
influenzae60 triggering an uncontrolled innate inflammatory
response.
The potential connection between the IL-6TS–high subset and
microbial colonization is supported by a recent publication
showing increased sputum bacterial numbers in a subset of
patients with asthma and chronic obstructive pulmonary disease,
the so-called cluster 2 or IL-1b–high cluster, which is also
characterized by significantly increased sputum IL-6 and sIL-6R
levels.44
In a replication cohort of patients with treatment-resistant
severe asthma all receiving high doses of inhaled steroids,43 the
IL-6TS–specific signature was present in nearly half of the pa-
tients, suggesting that the IL-6TS–high phenotype correlates
TABLE II. Clinical characteristics of the IL-6TS–high versus IL-6TS–low subsets from the Wessex Severe Asthma Cohort
Parameter IL-6TS-high IL-6TS-low P value
Group size 24 122
Female sex (%) 58.3 57.4 .93
Body mass index (kg/m2) 31.8 6 0.7 30.7 6 1.4 .57
Age (y) 46.5 6 2.6 51.3 6 1.1 .09
Current smokers (%) 8.3 8.2 .98
Never smokers (%) 50.0 48.4 .59
Pack years 10.2 6 3.7 9.9 6 1.3 .76
ICS dose (equivalent mg of BDP) 1940 (1600-2000) 1940 (1600-2060) .67
Maintenance OCS (%) 29 31 (n 5 119) .79
Prednisolone dose (among OCS users) 10 (10-10) 10 (5-15) 1.00
FEV1 (% predicted) 66.5 6 2.1 63.9 6 4.4 .62
Positive atopic status (%) 79.2 69.7 .35
Total IgE (IU/mL) 126 (25-384 [n 5 23]) 190 (68-531 [n 5 113]) .19
FENO (ppb) 23 (13.3-42.5 [n 5 23]) 14 (8.3-24.9 [n 5 109]) .023*
Blood eosinophils (3 1000/mL) 0.51 (0.34-0.91) 0.21 (0.11-0.49) .0008*
Blood eosinophils, >300/mL (%) 79.2 38.7 .0004*
Sputum eosinophils (%) 1 (0.33-7.65 [n 5 23]) 1.25 (0.25-8.5 [n 5 113]) .88
Sputum eosinophils >3% (%) 30.4 (n 5 23) 43.4 (n 5 113) .25
Sputum eosinophils >20% (%) 8.7 (n 5 23) 14.2 (n 5 113) .48
Blood neutrophils (3 1000/mL) 6.07 (3.9-7.5) 6.12 (4.4-8.1) .60
Sputum neutrophils (%) 68.4 (42.8-80.3) 45.4 (26.1-64.1) .010*
Sputum neutrophils >60% (%) 62.5 31.1 .004*
Sputum macrophages (%) 18.8 (6.7-36.5) 36.2 (23.6-56.0) .009*
Data are presented as percentage, means 6 SEs, or medians (interquartile ranges [Q1-Q3]). Number of subjects is 24 in the IL-6TS–high subset and 122 in the IL-6TS–low subset,
unless stated otherwise. For P values, the Kruskal-Wallis test was used for continuous data, and the x2 test was used for categorized data.
BDP, Beclomethasone dipropionate; FENO, fraction of exhaled nitric oxide; ICS, inhaled corticosteroids; OCS, oral corticosteroids.
*Statistically significant (P <_ .05).
Statistical tests were performed on transformed data.
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of patients with mild-to-moderate and severe asthma,41,42 the IL-
6TS–high subset overlapped with the majority of patients with se-
vere asthma, further strengthening the association of epithelial
IL-6TS with asthma severity.
It should be noted that identification of the IL-6TS–high subset
in the U-BIOPRED cohort was based on a relatively small number
of epithelial brushings with available transcriptomic data. To
overcome this limitation, we validated the findings from U-
BIOPRED in a larger sputum biomarker data set obtained from
the Wessex Severe Asthma Cohort.22 In this cohort a putative IL-
6TS–high subset was identified by using hierarchical clustering of
asthmatic patients based on levels of the IL-6TS surrogate bio-
markers YKL-40, MMP3, IL-8, MIP-1b, and IL-1b in induced
sputum. As in U-BIOPRED, the Wessex IL-6TS–high patients
were characterized by blood eosinophilia, without a significant in-
crease in levels of T2 biomarkers. Furthermore, the IL-6TS–high
subset was associated with increased sputum neutrophil counts,
supporting the connection between IL-6 signaling and neutro-
philic inflammation proposed by other studies.19,39 Finally, the
significantly increased sputum levels of sIL-6R and IL-6 directly
link the Wessex IL-6TS–high subset to a local IL-6–driven in-
flammatory response.
The role of local IL-6 signaling as a disease driver in patients
with chronic airway disease is supported further by a transgenic
mouse model driven by local overexpression of IL-6 in lung
tissue. These mice showed emphysema-like airspace enlarge-
ment, thickening of the airway walls, subepithelial airwayfibrosis, and accumulation of mononuclear immune cells in the
peribronchiolar space.61
In conclusion, we used an IL-6TS–specific epithelial gene
signature to identify and describe a novel asthmatic patient subset
with IL-6TS pathway activation in the lung epithelium as a
biological driver. We showed that these patients constitute a
molecular phenotype characterized by an increased exacerbation
rate, T2 inflammation–independent eosinophilia, increased sub-
mucosal inflammation, activation of innate signaling pathways,
increased markers of airway remodeling, and decreased expres-
sion of epithelial junctions components. This novel IL-6TS–high
asthma subset appears to be associated with poor asthma control,
and our results might provide one further step toward a stratified
medicine approach to addressing a significant unmet medical
need in patients with severe asthma.
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d A subset of asthmatic patients (IL-6TS–high subset)
distinct from T2 asthma shows lung epithelial IL-6TS
pathway activation in the absence of systemic IL-6
inflammation.
d The IL-6TS–high subset constitutes a novel asthma
phenotype associated with frequent exacerbations, eosino-
philia, airway inflammation, remodeling, and impaired
epithelial integrity.
d Identification of local airway IL-6TS pathway activation
as a potential disease driver might open up a stratified
medicine approach to treating asthma.
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